Low-dose heparin for severe sepsis [2]

New England Journal of Medicine

Volumn 347, Issue 13, 2002, Pages 1036-1037

  Davidson, Bruce L ^a   Geerts, William H ^a   Lensing, Anthonie W A ^a  

^a SWEDISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; HEPARIN; PLACEBO;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG COST; HEPARINIZATION; HIGH RISK PATIENT; HUMAN; LETTER; PRIORITY JOURNAL; SEPSIS; SURVIVAL RATE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; HEPARIN; HUMANS; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS;

EID: 0037179708     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200209263471316     Document Type: Letter

References (5)

1. Bernard GR, Vincent J-L, Laterrie P-F, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
2. Ahmed T, Gonzalez BJ, Danta I. Prevention of exercise-induced bronchoconstriction by inhaled low-molecular-weight heparin. Am J Respir Crit Care Med 1999;160:576-81.
3. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340:207-14.
4. Anti-Infective Advisory Committee. FDA briefing document: drotrecogin alfa (activated) [recombinant human activated protein C (rhAPC)] Xigris. BLA #125029/0. Rockville, Md.: Food and Drug Administration, September 12, 2001. (Accessed September 6, 2002, at http://www.fda.gov/ ohrms/dockets/ac/01/briefing/3797b1_02_FDAbriefing.pdf.)
5. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient: high-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-78.